FIELD: biotechnology.
SUBSTANCE: proposed is an application of a T-cell redirecting bispecific therapeutic agent for treating gp100-positive cancer in a patient. The therapeutic agent comprises a targeting fragment constituting a T-cell receptor and binding the YLEPGPVTA-HLA-A2 complex fused with a T-cell redirecting fragment constituting an antibody against CD3.
EFFECT: dosing regimen of a T-cell redirecting bispecific therapeutic agent allows for treatment of gp100-positive cancer with improved tolerability in a patient.
10 cl, 10 dwg. 2 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW BISPECIFIC POLYPEPTIDE COMPLEXES AGAINST CD3/CD19 | 2018 |
|
RU2788127C2 |
| MULTI-CHAIN CHIMERIC ANTIGEN RECEPTOR AND USES THEREOF | 2013 |
|
RU2663725C2 |
| T-CELL RECEPTORS SPECIFIC RELATIVELY TO COMPLEX OF TUMOR ANTIGEN NY-ESO-1/HLA-A*02 | 2016 |
|
RU2775394C2 |
| SPECIFIC BINDING MOLECULES | 2020 |
|
RU2825837C2 |
| CD3-SPECIFIC BINDING MOLECULES | 2020 |
|
RU2826453C2 |
| T-CELL RECEPTORS | 2018 |
|
RU2762255C2 |
| T-CELL RECEPTORS | 2017 |
|
RU2775623C2 |
| TRISPECIFIC BINDING MOLECULES, WHICH SPECIFICALLY BIND ANTIGENS OF A VARIETY OF MALIGNANT TUMORS, AND METHODS OF USING THEM | 2015 |
|
RU2718692C2 |
| MONOCLONAL ANTIBODIES AND METHODS OF USING THEM | 2017 |
|
RU2694412C2 |
| PSCAXCD3, CD19XCD3, C-METXCD3, ENDOSIALIN XCD3, EPCAMXCD3, IGF-1RXCD3 OR FAP-ALPHA XCD3 BISPECIFIC SINGLE-CHAIN ANTIBODY WITH INTER-SPECIES SPECIFICITY | 2009 |
|
RU2547600C2 |
